New siRNA Nanotherapy
siRNA therapeutic
new clinical product
new avenues
siRNA nanotherapeutics
mean of siRNA
NEW DEAL solution
NEW DEAL project
better tolerability of siRNA
oral administration
siRNA-based therapy
IBD patients
clinical experts
clinical translation
Inflammatory Bowel Diseases
efficacy evaluation
improved efficacy
Clinical Development Plan
innovative SMEs
regulatory issues
increased safety
design of capsules
polymeric capsules
target cells
good convenience
target of great
Regulatory Submission Package
radical therapeutic progress
innovative nanostructured lipid carriers
established pharma company
Janus kinase
historic expertise
RNAi biology
leading scientists
future industrial transfer
Europe
transport
immunology
strong background
nanomedicine
nanosafety
thanks
term of immunogenicity
manufacturing
inflamed gut
late preclinical stage
gastroenterology medicinal products
plasma membrane
intestinal barrier
main drawbacks
specific JAK3 inhibition
common immune-mediated disorders
antibodies
mucus
safer manner
transit
GI tract
objectives
current therapies
young people
clinics
challenge